DNTH icon

Dianthus Therapeutics

17.86 USD
+1.03
6.12%
At close Apr 2, 4:00 PM EDT
After hours
17.86
+0.00
0.00%
1 day
6.12%
5 days
-3.04%
1 month
-8.97%
3 months
-23.02%
6 months
-36.17%
Year to date
-23.02%
1 year
-33.08%
5 years
177.33%
10 years
23.00%
 

About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Employees: 78

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 24

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

11.78% more ownership

Funds ownership: 106.9% [Q3] → 118.68% (+11.78%) [Q4]

4% more funds holding

Funds holding: 91 [Q3] → 95 (+4) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]

11% less capital invested

Capital invested by funds: $859M [Q3] → $766M (-$93.2M) [Q4]

31% less call options, than puts

Call options by funds: $9K | Put options by funds: $13K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$36
102%
upside
Avg. target
$53
199%
upside
High target
$84
370%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Laura Chico
19% 1-year accuracy
10 / 54 met price target
102%upside
$36
Outperform
Reiterated
12 Mar 2025
Guggenheim
Yatin Suneja
24% 1-year accuracy
8 / 34 met price target
370%upside
$84
Buy
Reiterated
12 Mar 2025
HC Wainwright & Co.
Swayampakula Ramakanth
18% 1-year accuracy
36 / 202 met price target
124%upside
$40
Buy
Reiterated
12 Mar 2025

Financial journalist opinion

Based on 3 articles about DNTH published over the past 30 days

Negative
Zacks Investment Research
3 weeks ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
3 weeks ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Neutral
GlobeNewsWire
4 weeks ago
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
Neutral
GlobeNewsWire
1 month ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Negative
Zacks Investment Research
4 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
4 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Neutral
GlobeNewsWire
4 months ago
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Neutral
GlobeNewsWire
5 months ago
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia.
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
Charts implemented using Lightweight Charts™